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Human metapneumovirus (hMPV) is an important 
cause of lower respiratory tract infections in hospitalized 
children, but the age-related incidence and effect of hMPV 
in unselected children in the community have not been 
evaluated. We studied a cohort of 1,338 children <13 years 
of age throughout 1 respiratory season in Finland during 
2000–2001. We examined children and obtained a nasal 
swab for viral detection at any sign of respiratory infection. 
hMPV was detected in 47 (3.5%) of the 1,338 children. The 
age-related incidence of hMPV infection was highest (7.6%) 
in children <2 years of age, in whom hMPV accounted for 
1.7% of all infections during the season. During the epidem-
ic peak, hMPV caused 7.1% of all respiratory infections in 
the cohort. Acute otitis media developed in 61% of hMPV-
infected children <3 years of age. Our ﬁ  ndings demonstrate 
that the effect of hMPV in the community is greatest in chil-
dren <2 years of age.
H
uman metapneumovirus (hMPV) was isolated in 2001 
by van den Hoogen et al. in previously virus-negative 
nasopharyngeal aspirates from children with respiratory 
tract infections (1). Since then, hMPV has been identiﬁ  ed 
wordwide (2–9). In temperate regions, hMPV circulates 
mainly during the winter (6,7,10–12). Clinical symptoms 
of hMPV infection resemble those caused by respiratory 
syncytial virus and range from mild upper respiratory tract 
infections to wheezing and severe lower respiratory tract 
illnesses that require hospitalization (4,5,10–14). Although 
hMPV infections have been diagnosed in all age groups, 
the virus likely has its greatest effect in children (13,14).
Several studies have demonstrated that hMPV ac-
counts for a major proportion of hospitalizations for lower 
respiratory tract infections in infants and young children 
(10,13,15,16). The most frequent diagnoses in hospitalized 
children are bronchiolitis and pneumonia, but occasionally 
hMPV may also cause severe illnesses that require treat-
ment at intensive care units (17,18).
Clinical features of hMPV infection in hospitalized 
children and the role of hMPV as a cause of hospitaliza-
tion have been well described. However, most children 
infected with hMPV are treated as outpatients. Although 
hMPV has been found in substantial numbers of selected 
outpatient children (12,19–21), to our knowledge, no pop-
ulation-based studies of the incidence and clinical effect 
of hMPV on unselected children of different ages have 
been conducted. We determined the incidence, clinical 
features, and total effect of hMPV infection in a large, 
prospective, cohort study of respiratory infections in chil-
dren in Finland.
Methods
Study Participants and Study Protocol
This prospective study was conducted in Turku, Fin-
land, from October 9, 2000, through May 20, 2001. The 
participating children were recruited before the start of the 
respiratory season in daycare centers, family daycare, and 
schools in our area (22). All children <13 years of age were 
eligible for participation; no exclusion criteria were used. 
Of 1,458 children initially enrolled, 1,338 were closely 
monitored throughout the entire follow-up period. The 
baseline characteristics of participating children are shown 
in Table 1.
Parents were asked to bring their children to the study 
clinic for examination by a study physician whenever fever 
or signs of respiratory tract infection appeared. The study 
clinic was open every day, and all visits were free. In addi-
tion to full clinical examination, chest or sinus radiographs 
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were obtained if pneumonia or sinusitis was suspected on 
the basis of clinical symptoms. Acute otitis media (AOM) 
was diagnosed by pneumatic otoscopy, aided by routine use 
of tympanometry and spectral-gradient acoustic reﬂ  ectom-
etry. Children without any complications at the ﬁ  rst visit 
were reexamined after 5–7 days, or whenever the parents 
deemed it necessary.
The parents were provided with a symptom diary in 
which they recorded daily the child’s symptoms and ab-
sences from daycare or school and the parents’ absences 
from work because of the child’s illness. Only actual days 
lost were recorded. Thus, days of illness occurring on free 
weekends or other days off were not recorded as causing 
absenteeism.
Viral Sampling
At each visit for a new respiratory tract infection, a na-
sal swab was obtained from a depth of 2–3 cm in the nostril 
by using a sterile cotton swab that was then inserted into 
a vial containing viral transport medium (23). The speci-
mens were kept in a refrigerator and transported daily to 
the laboratory at the Department of Virology, University 
of Turku, where they were subjected to viral culture for in-
ﬂ  uenza viruses, parainﬂ  uenza viruses, respiratory syncytial 
virus, and adenovirus, and PCR assays for rhinoviruses and 
enteroviruses. The specimens were then frozen at –70°C 
until thawed for the purposes of this study.
Detection of hMPV
RNA was extracted from nasal swab specimens by 
using a High Pure Viral Nucleic Acid Kit (Roche, Ba-
sel, Switzerland) according to the manufacturer’s proto-
col. hMPV was identiﬁ  ed in specimens by using reverse 
transcription–PCR (RT-PCR). Brieﬂ  y, hMPV was ampli-
ﬁ  ed in a 1-step RT-PCR. The RT-PCR mixture contained 
RT-PCR buffer (50 mmol/L Tris-HCl, pH 8.4, 50 mmol/L 
NaCl, 4 mmol/L MgCl2), 0.5 mmol/L MgCl2, 2 mmol/L 
dithiothreitol, 0.6 mmol/L deoxynucleoside triphosphates, 
1 μmol/L of each primer, 20 U Maloney murine leukemia 
virus reverse transcriptase (Promega, Madison, WI, USA), 
4 U Recombinant RNAsin ribonuclease inhibitor (Pro-
mega), and 1 U DyNAzyme (Finnzymes, Espoo, Finland). 
The total volume of the reaction mixture was 50 μL and 
contained 5 μL of extracted RNA. The RT-PCR for hMPV 
RNA was conducted at 42°C for 45 min, then at 95°C for 7 
min. cDNA ampliﬁ  cation consisted of 40 cycles (denatur-
ation at 95°C for 1 min, annealing at 58°C for 1 min, and 
extension at 72°C for 1 min) and ﬁ  nal extension at 72°C for 
10 min. Primers for hMPV were from the L gene (10), and 
the forward primer was biotinylated.
Biotinylated hMPV RT-PCR products were detected 
by using a liquid hybridization assay. In this assay, 10 μL 
of each RT-PCR product was mixed with 50 μL of DEL-
FIA assay buffer (PerkinElmer Finland Oy, Turku, Fin-
land), added to 3 parallel microtitration wells coated with 
streptavidin (PerkinElmer Finland Oy), and incubated at 
room temperature for 30 min. Wells were washed at room 
temperature with Tris-NaCl buffer containing 0.5% Tween 
20, denatured for 5 min with 150 μL denaturation buffer 
(25 mmol/L NaOH and 5 mmol/L EDTA), hybridized with 
Eu-labeled hMPV-probe (5′-CTG TTA ATA TCC CAC 
ACC AG-3′) at 40°C for 2 hours. The hybridization was 
performed with 100 μL of hybridization solution, in which 
2 ng Eu-labeled hMPV probe per well was diluted with 
DELFIA assay buffer that included 0.85 mmol/L NaCl and 
0.1% Tween 20. Unspeciﬁ  c hybridizations were removed 
with hot (50°C) Tris-NaCl buffer containing 0.5% Tween 
20. To enhance ﬂ  uorescence, 200 μL DELFIA Enhance-
ment solution (PerkinElmer Finland Oy) was added per 
well and incubated for 10 min with shaking. Fluorescence 
was measured by using a Victor 1420 Multilabel Counter 
(PerkinElmer Finland Oy).
Deﬁ  nitions
AOM was diagnosed by signs of inﬂ  ammation of the 
tympanic membrane, the presence of middle ear effusion, 
and >1 signs of acute infection. The diagnosis of pneumo-
nia was based on radiologic conﬁ  rmation of the condition. 
Both complications were associated with hMPV infection 
if they were diagnosed <14 days after the clinical visit at 
which the hMPV-positive specimen was obtained.
Ethics
The study protocol was reviewed and approved by the 
Ethics Committee of Turku University Hospital. Written 
informed consent was obtained from the parents of all par-
ticipating children.
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Table 1. Baseline characteristics of 1,338 children at beginning of 
follow-up, Finland, 2000–2001 
Variable No. children (%) 
Age, y 
<1 30 (2.2)
1–<2 219 (16.4) 
2–<4 362 (27.1) 
4–<6 247 (18.5) 
6–<9 232 (17.3) 
9–12 248 (18.5) 
Sex 
Male 692 (51.7) 
Female 646 (48.3) 
Child care 
Home or family daycare  261 (19.5) 
Daycare center  658 (49.2) 
School 419 (31.3) 
Diagnosis of asthma  72 (5.4) 
Previous wheezing  253 (18.9) 
Exposure to tobacco smoke  512 (39.1)*
*Information available for 1,310 children. Human Metapneumovirus Infections in Children
Results
hMPV Outbreak
The ﬁ  rst case of hMPV infection in the study cohort 
was identiﬁ  ed during the week of December 4, 2000, and 
the last case was identiﬁ  ed during the week of April 23, 
2001 (Figure 1). hMPV infections were diagnosed weekly 
over 14 consecutive weeks from January 8, 2001, through 
April 15, 2001. Overall, hMPV infection was diagnosed in 
47 children (26 boys and 21 girls). The median age of the 
children was 3.0 years; 81% were <5 years of age.
Incidence Rates of hMPV Infection 
in Different Age Groups
The incidence of hMPV infection was highest (7.6%) 
in children <2 years of age at the start of the respiratory 
season (Table 2). Of a subset of 30 children <1 year of age, 
3 (10.0%) acquired hMPV infection during follow-up. The 
incidence rates of hMPV decreased gradually with age. The 
overall incidence of hMPV infection in the study cohort 
of 1,338 children was 3.5% (95% conﬁ  dence interval [CI] 
2.5%–4.5%).
Relative Effect of hMPV among 
All Respiratory Infections
The relative proportion of hMPV infections among all 
respiratory infections was greatest in children <2 years of 
age, in whom hMPV accounted for 1.7% of all respiratory 
infections during the winter season (Table 3). During the 
14-week period of major hMPV circulation, hMPV ac-
counted for 4.2% of all infections in children <2 years of 
age. The relative effect of hMPV decreased with age. In 
the entire cohort of 1,338 children, hMPV accounted for 
1.3% (95% CI 0.9%–1.7%) of all respiratory infections 
during the whole respiratory season and 2.7% (95% CI 
1.9%–3.5%) of all infections during the 14-week period of 
continuous hMPV circulation.
The proportion of hMPV infections among all respira-
tory infections during each week of the study is shown in 
Figure 2. The relative effect of hMPV was highest during 
the week of February 19, during which the virus accounted 
for 7.1% of all respiratory infections in the study cohort.
Co-infections with hMPV
Another virus was detected concomitantly in 8 (17%) 
of 47 hMPV-infected children. Three children had entero-
virus, 2 had rhinovirus, and 1 each had inﬂ  uenza virus, 
parainﬂ  uenza virus, and a nontypeable picornavirus togeth-
er with hMPV.
Clinical Characteristics of hMPV Infection
The clinical ﬁ  ndings of hMPV infection were analyzed 
in 39 children in whom hMPV was the only virus detected 
(Table 4): 97% had a cough, 90% had rhinitis, and 72% had 
a fever. The median duration of symptomatic illness was 8 
days. AOM was the most frequently diagnosed complica-
tion; it occurred in 61% of children <3 years of age. Wheez-
ing was observed in 10% of the hMPV-infected children 
and laryngitis in 8%. A total of 38% of the children were 
treated with antimicrobial drugs. None of the children was 
referred to a hospital.
Socioeconomic Effect of hMPV
Overall, 54% of hMPV-infected children were absent 
from daycare or school for >1 day (Table 4). The mean 
duration of their absence was 3.3 days. In 38% of cases, a 
parent missed >1 day of work because of the child’s hMPV 
illness. The average duration of parental work loss was 2.9 
days.
Persistence of hMPV RNA in 
Nasal Swabs after Acute Illness
In 27 (57%) of the 47 children with hMPV infection, a 
follow-up nasal swab was obtained during a subsequent re-
spiratory infection. The median interval between the initial 
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Figure 1. Number of children with human metapneumovirus 
infections during each week of the study period, Finland, 2000–
2001.
Table 2. Incidence of human metapneumovirus (hMPV) 







Rate of hMPV/1,000 
children (95% CI) 
<2 249 19 76 (43–109) 
2–<4 362 14 39 (19–59) 
4–<6 247 9 36 (13–60) 
6–<9 232 3 13 (0–27) 
9–12 248 2 8 (0–19) 
Total 1,338 47 35 (25–45) 
*CI, confidence interval. 
†Age at beginning of follow-up. RESEARCH
hMPV-positive specimen and the subsequent sample was 
42 days (range 7–82 days). hMPV could not be detected in 
any of the subsequent samples after hMPV illness.
Discussion
This prospective cohort study provides new and de-
tailed information about the effects of hMPV infections 
in unselected children. Close clinical follow-up of a large 
cohort of children throughout an entire respiratory season 
enabled us to determine the incidence and relative impor-
tance of hMPV among all respiratory viruses in children in 
different age groups. A particular strength of our study was 
that we obtained samples for viral detection during every 
episode of respiratory illness seen at the study clinic, re-
gardless of the severity of the symptoms or the presence or 
absence of fever, thereby avoiding any bias caused by sam-
pling only a selected population of children with respira-
tory infections. Furthermore, symptoms of the children and 
the socioeconomic effect of their illnesses were recorded 
daily throughout the study period.
Our ﬁ  ndings demonstrate that the effect of hMPV in 
the community is greatest in the youngest children. The in-
cidence of hMPV infection in children <2 years of age was 
approximately twice that of children 2–5 years of age and 
10× higher than the incidence among children >9 years of 
age. This ﬁ  nding is consistent with those of serologic stud-
ies that demonstrated that most children contract hMPV by 
5 years of age (1,24,25). The effect of hMPV on the young-
est infants is likely even greater than what was observed in 
our study. In our cohort, the incidence of hMPV infection 
was highest in children <1 year of age, but the small num-
ber of children in this age group limits our drawing any 
ﬁ  rm conclusions about this ﬁ  nding.
In addition to the absolute incidence rates of hMPV be-
ing highest in children <2 years of age, the relative effect of 
hMPV among all respiratory viruses was greatest in this age 
group. During the period of continuous circulation of hMPV, 
this virus accounted for >4% of all respiratory infections in 
children <2 years of age. On an annual level, hMPV account-
ed for 1%–2% of all respiratory infections in our cohort. This 
estimate agrees with the results of a recent 20-year study in 
which the prevalence of hMPV ranged from 1% to 5% of all 
upper respiratory infections in a given year in children <5 
years of age (12). In our cohort, the overall effect of hMPV 
was substantially smaller than that of inﬂ  uenza  viruses, 
which accounted for ≈7% of all respiratory infections during 
the same winter season (26). However, the substantial effect 
of hMPV during local outbreaks is demonstrated by our ﬁ  nd-
ing that during the peak of the epidemic, hMPV was respon-
sible for 7% of all respiratory infections in the children even 
though inﬂ  uenza virus was circulating in the community at 
the same time (26).
Most children with hMPV had cough, rhinitis, and fe-
ver. In contrast with previous reports of a high prevalence 
of wheezing in hospitalized children (4,5,7,10,13), only 
10% of the children seen in primary care had wheezing, and 
none of these children was referred to a hospital. This is 
understandable because patients with more severe illnesses 
usually end up in hospitals, but these results also indicate 
that most hMPV infections in children are relatively mild 
and clinically indistinguishable from other viral infections. 
Of importance, however, is the high rate of AOM as a com-
plication of hMPV infection. Together with similar reports 
by other investigators (12,13,27), hMPV has a particularly 
strong ability to predispose a child to AOM. This under-
scores the clinical similarity between hMPV and respira-
tory syncytial virus, which is also a major viral cause of 
AOM in children (28–30).
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Table 3. Proportions of human metapneumovirus (hMPV) infections in children, Finland, 2000–2001 
Whole respiratory season  Major hMPV outbreak†
Age, y*  Total no. specimens 
No. hMPV-positive
specimens (%)  Total no. specimens 
No. hMPV-positive
specimens (%) 
<2 1,107 19 (1.7)  430 18 (4.2) 
2–<4 1,156 14 (1.2)  518 12 (2.3) 
4–<6 631 9 (1.4)  309 9 (2.9) 
6–<9 420 3 (0.7)  194 3 (1.5) 
9 –12  307 2 (0.7)  151 2 (1.3) 
All children  3,621 47 (1.3)  1,602 44 (2.7) 
*Age at beginning of follow-up. 
†Period of 14 consecutive weeks during which hMPV infections were detected every week in the children. 
Figure 2. Weekly proportions of human metapneumovirus infections 
among all respiratory infections in the study children, Finland, 
2000–2001.Human Metapneumovirus Infections in Children
In previous studies, hMPV has been infrequently de-
tected in asymptomatic children (10,13). We could not de-
tect hMPV in any samples obtained during a subsequent 
respiratory infection after hMPV illness. These ﬁ  ndings 
imply that hMPV in the nasal mucosa is short-lived and 
corroborate the view that detection of hMPV RNA in respi-
ratory secretions is strongly indicative of a causal role for 
the virus in the illness.
The variation in prevalence of hMPV from season to 
season has been demonstrated (12,13). Therefore, our re-
sults obtained during 1 winter season are not directly gen-
eralizable to all other winters. However, on the basis of a 2-
year hospital-based study in our area, circulation of hMPV 
was substantially greater during the winter of 2000–2001 
than during the following winter (31). Thus, our season of 
follow-up likely did not represent a season with exception-
ally low hMPV activity. We obtained nasal swabs instead 
of nasopharyngeal aspirates for reasons of compliance with 
repeated sampling. The sensitivity of nasal swabs for detec-
tion of various respiratory viruses is ≈90% compared with 
nasopharyngeal aspirates (23). Therefore, some cases of 
hMPV may not have been diagnosed. Furthermore, because 
we did not use serologic analysis, we have no data on the 
incidence of hMPV infections that were either asymptom-
atic or so mild that the parents did not bring the children to 
the study clinic. However, the clinical importance of such 
subclinical infections is negligible.
In conclusion, our prospective population-based study 
provides conclusive evidence for the effect of hMPV infec-
tions in children. The effect of hMPV is greatest in children 
<2 years of age. hMPV also appears to be one of the major 
viruses predisposing children to AOM. Although on an an-
nual level hMPV accounts only for a small proportion of all 
respiratory infections in children, its relative role among all 
respiratory viruses is substantial during local hMPV out-
breaks.
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